Septerna, Inc. (NASDAQ:SEPN) Receives $52.44 Average Price Target from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have received a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $52.4444.

SEPN has been the topic of several analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. Guggenheim boosted their price target on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Truist Financial upped their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. raised their price objective on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Finally, Wells Fargo & Company lifted their target price on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th.

Septerna Price Performance

NASDAQ:SEPN opened at $40.25 on Friday. The company’s fifty day moving average price is $37.15 and its 200-day moving average price is $30.65. Septerna has a 1-year low of $11.70 and a 1-year high of $51.10. The firm has a market capitalization of $1.88 billion, a P/E ratio of -74.54 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. Equities analysts anticipate that Septerna will post -1.41 EPS for the current fiscal year.

Insider Activity at Septerna

In other Septerna news, SVP Daniel D. Long sold 3,334 shares of Septerna stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the completion of the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $27,897.74. This trade represents a 73.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 61,030 shares of company stock worth $2,329,666. 5.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Septerna

A number of large investors have recently bought and sold shares of SEPN. Woodline Partners LP grew its holdings in Septerna by 94.2% in the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares during the period. Rhumbline Advisers raised its stake in shares of Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after buying an additional 3,323 shares during the period. Geode Capital Management LLC raised its stake in shares of Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after buying an additional 78,316 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC acquired a new stake in Septerna in the 2nd quarter valued at $133,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.